Navigation For Mobile

Category Archives: Freedom to Operate

Intellectual Property Management Group Focuses on API Innovation and Differentiation for Customers

With potential projected losses of $16-32 billion for drugs going off-patent in 2015, intellectual property (IP) is increasingly crucial to keeping a competitive edge in the pharmaceutical and biotechnology markets….

Posted in agreement, API synthesis, APIs, Chemistry, CMC, Contract Manufacturing, CRO/CMO, Freedom to Operate, IP, Patent, R&D, technology transfer | Comments Off on Intellectual Property Management Group Focuses on API Innovation and Differentiation for Customers

Generic Drugs – The Freedom to Operate

In a recent post about contract manufacturing and IP, I discussed how Neuland doesn’t compete with clients in the generics space. A friend in Pharma subsequently asked me my thoughts…

Posted in Contract Manufacturing, Freedom to Operate, IP, Patent | Comments Off on Generic Drugs – The Freedom to Operate